2006
Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction
Nikolsky E, Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Negoita M, Lansky AJ, Mehran R. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. American Heart Journal 2006, 151: 168-175. PMID: 16368312, DOI: 10.1016/j.ahj.2005.03.024.Peer-Reviewed Original ResearchConceptsPrimary percutaneous coronary interventionPrimary PCIBody mass indexAcute myocardial infarctionNormal weight patientsBaseline body mass indexObese patientsMyocardial infarctionCreatinine clearanceMass indexNon-anterior myocardial infarctionAnterior acute myocardial infarctionLower inhospital mortalityGood renal functionHigher creatinine clearanceLower creatinine clearanceBlood product transfusionLow ejection fractionPercutaneous coronary interventionCADILLAC trialHours onsetInhospital mortalityHemorrhagic complicationsPrimary angioplastyProduct transfusion
2005
Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction
Nikolsky E, Sadeghi HM, Effron MB, Mehran R, Lansky AJ, Na Y, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD, Grines CL, Stone GW. Impact of In-Hospital Acquired Thrombocytopenia in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction. The American Journal Of Cardiology 2005, 96: 474-481. PMID: 16098296, DOI: 10.1016/j.amjcard.2005.04.005.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAge DistributionAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalCause of DeathFemaleFollow-Up StudiesHemorrhageHumansImmunoglobulin Fab FragmentsIncidenceInpatientsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPlatelet CountProspective StudiesRisk FactorsSex DistributionSurvival RateThrombocytopeniaTreatment OutcomeConceptsPrimary percutaneous coronary interventionPercutaneous coronary interventionAcute myocardial infarctionHemorrhagic complicationsAcquired thrombocytopeniaPlatelet countMyocardial infarctionHigher baseline platelet countGreater body mass indexNadir platelet countPrevious aspirin useUse of abciximabBaseline platelet countBlood product transfusionLonger hospital stayMajor hemorrhagic complicationsHours of onsetBody mass indexAspirin useBaseline thrombocytopeniaCADILLAC trialIschemic complicationsCause mortalityHospital stayPrimary angioplasty
2004
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial
Nikolsky E, Aymong ED, Halkin A, Grines CL, Cox DA, Garcia E, Mehran R, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Cohen DA, Negoita M, Lansky AJ, Stone GW. Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention Analysis from the controlled abciximab and device investigation to lower late angioplasty complications (cadillac) trial. Journal Of The American College Of Cardiology 2004, 44: 547-553. PMID: 15358018, DOI: 10.1016/j.jacc.2004.03.080.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAnemiaAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood Component TransfusionFemaleHematocritHemorrhageHospital MortalityHumansImmunoglobulin Fab FragmentsIncidenceMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPlatelet Aggregation InhibitorsPredictive Value of TestsPrognosisRandomized Controlled Trials as TopicStentsStrokeSurvival AnalysisTreatment OutcomeConceptsPrimary percutaneous coronary interventionAcute myocardial infarctionPrimary PCILate Angioplasty Complications (CADILLAC) trialImpact of anemiaComplications TrialMyocardial infarctionWorld Health Organization criteriaPrimary PCI outcomesBlood product transfusionOne-year mortalityBaseline laboratory valuesPercutaneous coronary interventionPresence of anemiaBaseline anemiaControlled AbciximabHospital mortalityProduct transfusionHemorrhagic complicationsIndex hospitalizationCoronary interventionIndependent predictorsPCI outcomesPrognostic importanceAdverse outcomes